Key result
Active cardiac sarcoidosis on MR(+)PET(+) links to ~4.8-fold higher odds of 6-month adverse events.
Why the study?
Invasive endomyocardial biopsy has poor sensitivity for diagnosing cardiac sarcoidosis due to patchy disease distribution. Hybrid LGE MR and 18F-FDG PET imaging shows promise for diagnosing active disease, requiring evaluation of an extended qualitative and quantitative imaging strategy and its association with cardiac-related outcomes.
Cohort (n=148)
No
Answers are grounded in this paper and cite their sources.
Shows hybrid MR and PET imaging identifies active cardiac sarcoidosis linked to adverse cardiac events at six months, indicating potential for risk stratification.
Objectives To evaluate an extended hybrid MR/PET imaging strategy in cardiac sarcoidosis (CS) employing qualitative and quantitative assessment of PET tracer uptake, and to evaluate its association with cardiac-related outcomes. Background Invasive endomyocardial biopsy is the gold standard to diagnose CS, but it has poor sensitivity due to the patchy distribution of disease. Imaging with hybrid late gadolinium enhancement (LGE) MR and 18 F-fluorodexyglucose ( 18 F-FDG) PET allows simultaneous assessment of myocardial injury and disease activity and has shown promise for improved diagnosis of active CS based on the combined positive imaging outcome, MR(+)PET(+). Methods 148 patients with suspected CS were enrolled for hybrid MR/PET imaging. Patients were classified based on presence/absence of LGE (MR+/MR-), presence/absence of 18 F-FDG (PET+/PET-), and pattern of 18 F-FDG uptake (focal/diffuse) into the following categories: MR(+)PET(+) FOCAL , MR(+)PET(+) DIFFUSE , MR(+)PET(-), MR(-)PET(+) FOCAL , MR(-)PET(+) DIFFUSE , MR(-)PET(-). Patients classified as MR(+)PET(+) FOCAL were designated as having active CS [aCS(+)], while all others were considered as having inactive or absent CS and designated aCS(-). Quantitative values of standard uptake value (SUVmax), target-to-background ratio (TBRmax), target-to-normal-myocardium ratio (TNMRmax) and T2 were measured. Occurrence of a cardiac-related clinical outcome was defined as any of the following during the 6-month period after imaging: cardiac arrest, ventricular arrhythmia, complete heart block, need for cardiac resynchronization/defibrillator/pacemaker/monitoring device (CRT-D, ICD/WCD, or ILR). MR/PET imaging results were compared to the presence of the composite clinical outcome. Results Patients designated aCS(+) had more than 4-fold increased odds of meeting the clinical endpoint compared to aCS(-) (unadjusted odds ratio 4.8; 95% CI 2.0-11.4; p<0.001). TNMRmax achieved an area under the receiver operating characteristic curve of 0.90 for separating aCS(+) from aCS(-). Conclusions Hybrid MR/PET imaging with an extended image-based classification of CS was statistically associated with clinical outcomes in CS. TNMRmax had high sensitivity and excellent specificity for quantifying the imaging-based classification of active CS. Condensed Abstract Imaging with hybrid late gadolinium enhancement (LGE) MR and 18 F-fluorodexyglucose ( 18 F-FDG) PET allows simultaneous assessment of myocardial injury and disease activity and has shown promise for improved diagnosis of active cardiac sarcoidosis (CS). In this study, 148 patients with suspected CS were enrolled for hybrid MR/PET imaging. Patients were classified based on presence/absence of LGE (MR+/MR-), presence/absence of 18 F-FDG (PET+/PET-), and pattern of 18 F-FDG uptake (focal/diffuse). Patients classified as MR(+)PET(+) FOCAL were designated as having active CS and, compared to patients with any other imaging pattern, they had more than 4-fold increased odds of cardiac-related outcome at 6 months from imaging.
No takes yet. Share an insight, caveat, or question.
Trivieri et al. (2022) conducted a cohort in Known or suspected cardiac sarcoidosis (n=148). Positive active cardiac sarcoidosis on hybrid MR/PET [MR(+)PET(+)FOCAL] vs. Inactive or absent cardiac sarcoidosis on hybrid MR/PET [aCS(-)] was evaluated on Composite clinical endpoint of cardiac-related death, aborted cardiac arrest, sustained ventricular arrhythmia, complete heart block, or cardiac device requirement at 6 months (OR 4.8, 95% CI 2.0-11.4, p=<0.001). Active cardiac sarcoidosis identified by focal hybrid MR(+)PET(+) imaging was associated with 4.8-fold higher odds of adverse cardiac outcomes at 6 months.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: